RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome
- Resource Type
- Article
- Source
- In
Clinical Lung Cancer July 2023 24(5):415-428 - Subject
- Language
- ISSN
- 1525-7304